Small Pharmaceuticals
Market Cap
₹2,032 ₹2,032 Cr.
P/E
23.76
PEG
2.20
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis comes alive if Pharmaceuticals segment revenue and consolidated EBITDA margin deliver the specified Q2 FY27 signals, validating the operating-growth and scale-benefit assumptions.- The bull path depends on Pharmaceuticals strength and sustained margin improvement, while the bear path reflects Pharmaceuticals weakness, consolidated margin pressure, or execution disruption during the leadership transition.

Key Ratios

Market cap
Market cap
2,032 Cr
PE
PE
23.76
Prom Holding
Prom Holding
50.57 %
ROE (%)
ROE (%)
14.45
ROCE (%)
ROCE (%)
18.75
Div Yield (%)
Div Yield (%)
-
Sales
Sales
497 Cr
OPM (%)
OPM (%)
17.64 %
Debt to Equity
Debt to Equity
0.01
Institutions
Institutions
0.35 %
Individual < 2 lac
Individual < 2 lac
38.39 %
No. of Shareholders
No. of Shareholders
4.22 L

About

Syncom Formulations (India) Ltd. is a pharmaceutical company that manufactures and markets a w… Read more
Low
10
52W Range
High
23
  • Syncom Formulations
  • Sakar Healthcare
  • Venus Remedies

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Capex

Drug Delivery Break-Up

Raw Material Break-Up

Asset Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Syncom Formulations (India) Ltd. Business

Syncom Formulations (India) Ltd. specializes in manufacturing and marketing a wide range of pharmaceutical products in various dosage forms such as tablets, capsules, liquids, injectibles, and herbal products.

Syncom Formulations major competitors are Sakar Healthcare, Venus Remedies, Panacea Biotec, Jagsonpal Pharma, Fredun Pharma, Beta Drugs, Indoco Remedies.
Market Cap of Syncom Formulations is ₹2,032 Crs.
While the median market cap of its peers are ₹2,390 Crs.

Syncom Formulations seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Aug Sep
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material